Table 8. Open in new tab MIC and...

						Susceptibility
Amoxicillin	48	0.12	4	≤0.015	8	89.6	8.3	2.1	89.6	NA	NA	NA
AMC^a	48	0.12	4	≤0.015	8	87.5	8.3	4.2	87.5 (95.8)	NA	NA	NA
Azithromycin	48	16	>256	0.12	>256	47.9	0	52.1	NA	NA	NA	NA
Cefaclor	48	2	128	0.12	>256	39.6	16.7	43.8	31.3	0	31.3	68.8
Cefepime	48	0.5	2	≤0.015	2	81.3	18.8	0	NA	81.3	18.8	0
Cefixime	48	4	32	0.06	256	NA	NA	NA	31.3	NA	NA	NA
Cefpodoxime	48	0.5	4	≤0.015	16	50.0	8.3	41.7	50.0	33.3	16.7	50.0
Ceftriaxone	48	0.25	2	0.008	4	89.6	8.3	2.1	89.6	77.1	20.8	2.1
Cefuroxime	48	0.5	4	≤0.015	16	54.2	20.8	25.0	54.2	47.9	6.3	45.8
Ciprofloxacin	48	1	4	0.5	>32	NA	NA	NA	70.8	0	89.6	10.4
Clarithromycin	48	8	>256	0.06	>256	43.7	0	56.3	NA	NA	NA	NA
Levofloxacin	48	0.5	1	0.12	32	97.9	0	2.1	97.9	97.9	0	2.1
Moxifloxacin	48	0.12	0.12	0.06	2	97.9	2.1	0	97.9	97.9	0	2.1
Penicillin (oral)	48	0.5	4	≤0.015	4	33.3	41.7	25.0	NA	33.3	54.2	12.5
Penicillin (iv)	48	0.12	4	≤0.015	8	87.5	12.5	0	NA	56.3–87.5	NA	NA
Erythromycin^b	48	NT	NT	NT	NT	50.0	12.5	37.5	NA	50.0	6.3	43.7

Susceptibility

MIC (mg/L)

CLSI

PK/PD

EUCAST

Antimicrobial

50%

90%

min

max

Amoxicillin

0.12

≤0.015

89.6

8.3

2.1

89.6

AMC^a

0.12

≤0.015

87.5

8.3

4.2

87.5 (95.8)

Azithromycin

>256

0.12

>256

47.9

52.1

Cefaclor

128

0.12

>256

39.6

16.7

43.8

31.3

68.8

Cefepime

0.5

≤0.015

81.3

18.8

81.3

18.8

Cefixime

0.06

256

31.3

Cefpodoxime

0.5

≤0.015

50.0

8.3

41.7

50.0

33.3

16.7

50.0

Ceftriaxone

0.25

0.008

89.6

8.3

2.1

89.6

77.1

20.8

2.1

Cefuroxime

0.5

≤0.015

54.2

20.8

25.0

54.2

47.9

6.3

45.8

Ciprofloxacin

0.5

>32

70.8

89.6

10.4

Clarithromycin

>256

0.06

>256

43.7

56.3

Levofloxacin

0.5

0.12

97.9

2.1

97.9

2.1

Moxifloxacin

0.12

0.06

97.9

2.1

97.9

2.1

Penicillin (oral)

0.5

≤0.015

33.3

41.7

25.0

33.3

54.2

12.5

Penicillin (iv)

0.12

≤0.015

87.5

12.5

56.3–87.5

Erythromycin^b

50.0

12.5

37.5

50.0

6.3

43.7

						Susceptibility
Amoxicillin	48	0.12	4	≤0.015	8	89.6	8.3	2.1	89.6	NA	NA	NA
AMC^a	48	0.12	4	≤0.015	8	87.5	8.3	4.2	87.5 (95.8)	NA	NA	NA
Azithromycin	48	16	>256	0.12	>256	47.9	0	52.1	NA	NA	NA	NA
Cefaclor	48	2	128	0.12	>256	39.6	16.7	43.8	31.3	0	31.3	68.8
Cefepime	48	0.5	2	≤0.015	2	81.3	18.8	0	NA	81.3	18.8	0
Cefixime	48	4	32	0.06	256	NA	NA	NA	31.3	NA	NA	NA
Cefpodoxime	48	0.5	4	≤0.015	16	50.0	8.3	41.7	50.0	33.3	16.7	50.0
Ceftriaxone	48	0.25	2	0.008	4	89.6	8.3	2.1	89.6	77.1	20.8	2.1
Cefuroxime	48	0.5	4	≤0.015	16	54.2	20.8	25.0	54.2	47.9	6.3	45.8
Ciprofloxacin	48	1	4	0.5	>32	NA	NA	NA	70.8	0	89.6	10.4
Clarithromycin	48	8	>256	0.06	>256	43.7	0	56.3	NA	NA	NA	NA
Levofloxacin	48	0.5	1	0.12	32	97.9	0	2.1	97.9	97.9	0	2.1
Moxifloxacin	48	0.12	0.12	0.06	2	97.9	2.1	0	97.9	97.9	0	2.1
Penicillin (oral)	48	0.5	4	≤0.015	4	33.3	41.7	25.0	NA	33.3	54.2	12.5
Penicillin (iv)	48	0.12	4	≤0.015	8	87.5	12.5	0	NA	56.3–87.5	NA	NA
Erythromycin^b	48	NT	NT	NT	NT	50.0	12.5	37.5	NA	50.0	6.3	43.7

Table 8.

Open in new tab

MIC and susceptibility results for all S. pneumoniae isolates from the UAE

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
Amoxicillin	48	0.12	4	≤0.015	8	89.6	8.3	2.1	89.6	NA	NA	NA
AMC^a	48	0.12	4	≤0.015	8	87.5	8.3	4.2	87.5 (95.8)	NA	NA	NA
Azithromycin	48	16	>256	0.12	>256	47.9	0	52.1	NA	NA	NA	NA
Cefaclor	48	2	128	0.12	>256	39.6	16.7	43.8	31.3	0	31.3	68.8
Cefepime	48	0.5	2	≤0.015	2	81.3	18.8	0	NA	81.3	18.8	0
Cefixime	48	4	32	0.06	256	NA	NA	NA	31.3	NA	NA	NA
Cefpodoxime	48	0.5	4	≤0.015	16	50.0	8.3	41.7	50.0	33.3	16.7	50.0
Ceftriaxone	48	0.25	2	0.008	4	89.6	8.3	2.1	89.6	77.1	20.8	2.1
Cefuroxime	48	0.5	4	≤0.015	16	54.2	20.8	25.0	54.2	47.9	6.3	45.8
Ciprofloxacin	48	1	4	0.5	>32	NA	NA	NA	70.8	0	89.6	10.4
Clarithromycin	48	8	>256	0.06	>256	43.7	0	56.3	NA	NA	NA	NA
Levofloxacin	48	0.5	1	0.12	32	97.9	0	2.1	97.9	97.9	0	2.1
Moxifloxacin	48	0.12	0.12	0.06	2	97.9	2.1	0	97.9	97.9	0	2.1
Penicillin (oral)	48	0.5	4	≤0.015	4	33.3	41.7	25.0	NA	33.3	54.2	12.5
Penicillin (iv)	48	0.12	4	≤0.015	8	87.5	12.5	0	NA	56.3–87.5	NA	NA
Erythromycin^b	48	NT	NT	NT	NT	50.0	12.5	37.5	NA	50.0	6.3	43.7

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
Amoxicillin	48	0.12	4	≤0.015	8	89.6	8.3	2.1	89.6	NA	NA	NA
AMC^a	48	0.12	4	≤0.015	8	87.5	8.3	4.2	87.5 (95.8)	NA	NA	NA
Azithromycin	48	16	>256	0.12	>256	47.9	0	52.1	NA	NA	NA	NA
Cefaclor	48	2	128	0.12	>256	39.6	16.7	43.8	31.3	0	31.3	68.8
Cefepime	48	0.5	2	≤0.015	2	81.3	18.8	0	NA	81.3	18.8	0
Cefixime	48	4	32	0.06	256	NA	NA	NA	31.3	NA	NA	NA
Cefpodoxime	48	0.5	4	≤0.015	16	50.0	8.3	41.7	50.0	33.3	16.7	50.0
Ceftriaxone	48	0.25	2	0.008	4	89.6	8.3	2.1	89.6	77.1	20.8	2.1
Cefuroxime	48	0.5	4	≤0.015	16	54.2	20.8	25.0	54.2	47.9	6.3	45.8
Ciprofloxacin	48	1	4	0.5	>32	NA	NA	NA	70.8	0	89.6	10.4
Clarithromycin	48	8	>256	0.06	>256	43.7	0	56.3	NA	NA	NA	NA
Levofloxacin	48	0.5	1	0.12	32	97.9	0	2.1	97.9	97.9	0	2.1
Moxifloxacin	48	0.12	0.12	0.06	2	97.9	2.1	0	97.9	97.9	0	2.1
Penicillin (oral)	48	0.5	4	≤0.015	4	33.3	41.7	25.0	NA	33.3	54.2	12.5
Penicillin (iv)	48	0.12	4	≤0.015	8	87.5	12.5	0	NA	56.3–87.5	NA	NA
Erythromycin^b	48	NT	NT	NT	NT	50.0	12.5	37.5	NA	50.0	6.3	43.7

min, minimum; max, maximum; AMC, amoxicillin/clavulanic acid; S, susceptible; I, intermediate; R, resistant; NT, not tested; NA, no breakpoint data available (NA for azithromycin and clarithromycin by EUCAST because Etest^® breakpoints in CO₂ not available).

^aPK/PD susceptibility at high dose is shown in parentheses.

^bUsing S/I/R zone diameters of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).

This Feature Is Available To Subscribers Only